preoperatively, 10 days after RP and 12 months after RP. Pre-and postoperative SPLs were compared using paired Student's t-test. Predictors of PL shortening at 10 days and at 12 months after RP were evaluated on univariate and multivariate analyses.
INTRODUCTION AND OBJECTIVES: Primary urethral cancers account for less than 1% of all GU cancers. Due to the rarity of this condition, the literature is limited to retrospective case series and case reports. Therefore we sought to characterize female urethral cancer in a contemporary cohort. METHODS: Years 2004 -2013 of the National Cancer Database (NCDB) were used to identify primary urethral neoplasms among women. Clinicopathologic variables including age, race, tumor histology, grade, and treatment modality were analyzed. Overall survival (OS) was estimated using the Kaplan-Meier method. Associations with survival were evaluated using Cox regression models.
RESULTS: Between 2004 and 2013 there were 1,088 cases of primary female urethral cancer in NCDB. The median age at diagnosis was 66 years (IQR 56, 77) and the majority of women were Caucasian (66%) or African-American (30%). Adenocarcinoma (AC) was the most common histologic subtype (34%), followed by squamous (SCC) (26%) and urothelial cell carcinoma (UC) (25%). Women with AC were younger (63 years vs 69 for UC and 67 for SCC, p<0.001) and more likely to be African American (56.0 % vs 24.2%, p<0.001). At diagnosis 45% of all patients were cT3 and 38% were clinical stage III or higher. 16.6% had clinical node positive disease while 8.8% had distant metastatic disease. Among those with AC 56.8% were cT3 compared to 48.2% of SCC and 35% with UC (p<0.001). Patients with AC were most likely to undergo definitive surgery (72% vs 68% for UC and 59% for SCC, p¼0.0067). Conversely, those with SCC were more likely to be treated with primary chemo-radiation (16% vs 7% of AC and 5% of UC, p<0.0001). Nearly 44% of patients with SCC received radiation therapy during treatment compared to 37% and 21% of AC and UC patients respectively (p<0.0001). Median survival for those living was 47 months while 5 year OS was 41%. By subtype, 5 year OS for AC was worse than SCC or UC ( Figure 1 ) (Log-Rank 0.013). On multivariate analysis, after adjusting for clinical TNM stage, race, age, and treatment modality, histology was no longer significantly associated with overall survival (p¼0.57).
CONCLUSIONS: Patients with AC are younger, more likely to be African American, and present at a later stage than those with SCC or UC. Five year overall survival is poor regardless of histology, but worse among those with AC.
Source of Funding: none

PD49-12 PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: MANAGEMENT AND LONG-TERM OUTCOMES AT A TERTIARY REFERRAL CENTER
Brian Montgomery*, Derek Lomas, Vidit Sharma, Deborah Lightner, Rochester, MN INTRODUCTION AND OBJECTIVES: Malignant melanoma of the female urethra is a rare tumor. There is limited data regarding management and outcomes of this condition. We therefore sought to evaluate the management and outcomes of urethral melanoma in females at our institution.
METHODS: A retrospective analysis was performed of all women presenting to a tertiary referral center with primary malignant melanoma of the urethra from 1950 to 2016. All patients with identifiable e978 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 metastatic disease at time of diagnosis were excluded. We evaluated pathology, tumor characteristics, presenting symptoms, initial and subsequent treatments, tumor recurrences, and survival. RESULTS: A total of 23 women (median age 71; range 51, 86) were identified with a pathologic diagnosis of malignant melanoma of the urethra. Median width of the urethral mass was 2.2 cm (IQR 1.4, 3.0) with a median depth of invasion of 7 mm (IQR 3, 12) . The majority of masses involved the distal urethra (83%, 19/23), while four involved the entire urethra (17%). Concurrent vaginal involvement (pathologic T3) was present in 65% of patients (15/23). Reason for presentation to clinic include bleeding (74%, 17/23), mass (17% 4/23), pain (13%, 3/23), and voiding difficulty (4%, 1/23). All patients underwent surgical resection as first line therapy (65% partial urethrectomy, 26% radical urethrectomy, 9% anterior exenteration). Fifteen (65%) patients had recurrence of disease at a median of 7 months (IQR 4, 13) . Local recurrence occurred in 80% of patients (12/15). Metastatic disease was identified in 60% of patients (9/15) with lungs being the most common site (78%, 7/9), followed by inguinal lymph nodes (44%, 4/9) and brain (33%, 3/9). Metastatic disease occurred at a median of 5 months (IQR 3, 25). A total of thirteen patients died secondary to melanoma (65%, 13/20). Median overall survival is 25 months (IQR 9, 53) and cancer specific survival is 53 months (IQR 12, 72).
CONCLUSIONS: Malignant melanoma of the urethra in females commonly recurs (65%) with a large proportion of those patients progressing to metastatic disease (80%) at a median of 5 months after initial surgical resection. These patients should be closely monitored for development of systemic disease with timely initiation of adjuvant therapies. 
Source of Funding: None
INTRODUCTION AND OBJECTIVES:
To compare the clinical outcome between midurethtral sling procedure for stress urinary incontinence with and without concomitant repair of asymptomatic grade II pelvic organ prolapse (cystocele) repair.
METHODS: Seventy two female patients with stress urinary incontinence (SUI) and asymptomatic grade II cystocele were included in a randomized study between June 2014 and June 2015. They were divided equally into two groups. Group (A) treated only with transobturator tape (TOT) without treatment of the cystocele while in group (B) TOT was associated with cystocele repair by a tailored proline mesh. Postoperative follow up was performed after 3, 6 and 12 months. The two groups were compared regarding clinical outcome of SUI (cure, improvement or failure) and development of any denovo events.
RESULTS: For clinical outcomes based on patients' subjective symptoms, the cure rate of group (A) was 77.8%.66.7% and 66.7% meanwhile for group (B) was 85%,90% and 90% at 3,6 and 12 months, respectively (p<0.05). Cystocele was cured in all patients in group (B). Six patients (17%) with asymptomatic cystocele grade II in group (A) became symptomatic or with a higher grade at 6 months duration that required surgical repair. Denovo urgency with or without UUI was 12.5% in group (A) increasing up to 50% at 6 months follow up which was treated with anticholenergic medications, but was 5% in group (B) with highly stastistically significant difference (p<0.05).
CONCLUSIONS: Concomitant asymptomatic cystocele repair with midurethral sling improve the cure rate of stress urinary insentience, reduce the incidence of denovo urgency incontinence and worsening of existing cystocele. 
Source of
INTRODUCTION AND OBJECTIVES:
Obesity has been associated with urinary incontinence and may worsen incontinence related complaints following robotic sacral colpopexy (RSC). Elevated Body Mass Index (BMI) may confer an increased risk of denovo stress urinary incontinence (SUI) even when mid urethral sling (MUS) is performed. We sought to determine the risk of denovo stress incontinence following robotic sacral colpopexy in patients with elevated BMI and assess the impact of BMI on postoperative Quality of Life (QoL) metrics.
METHODS: Retrospective chart review was undertaken and continence and BMI are noted. BMI was stratified according to the NIH classification. Outcomes were patient reported SUI and pad use, development of denovo SUI after colpopexy, and decision to undergo MUS after RSC. Incontinence was defined as any mention of SUI at any
